Randox unveils cytokine tests
June 22, 2020—Randox Laboratories has unveiled cytokine testing for COVID-19 risk stratification and treatment monitoring.
Webinars and Sponsored Roundtables — Register Now
Tuesday, June 9, 2026, 1:00–2:00 PM ET
In this webinar, we will examine how immune recognition after allogeneic HCT can influence leukemia relapse and disease progression. The session will highlight the clinical relevance of HLA loss of heterozygosity (LOH), approaches used for its detection, and how LOH findings may support transplant strategies, including considerations for donor selection in subsequent transplantation.
Webinar presenter Alberto Cardoso Martins Lima, PhD, Clinical consulting scientist in histocompatibility,
specializing in allogeneic hematopoietic cell transplantation (HCT) at IGEN/AFIP São Paulo and CHC/UFPR in Curitiba, Brazil
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice
Webinar presenter Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, July 15, 2026, 1:00-2:00 PM ET
Hear an expert discuss how to integrate Kappa and Lambda in situ hybridization testing into your standard hematopathology workflow to accurately assess B-cell and plasma cell clonality. You will also gain the skills to recognize testing pitfalls in challenging reactive versus neoplastic proliferations and apply ancillary tools to resolve complex cases.
Webinar presenter Xiaojun Wu, MD, PhD, Assistant professor, Director of Hematopathology Section at NCR of Johns Hopkins Medicine Department of Pathology, SOM at Johns Hopkins University
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Randox Laboratories
Randox ToRCH quality controls get CE mark
June 10, 2020—Randox Laboratories ToRCH quality controls for infectious disease testing in newborns have been granted the CE mark.
Randox unveils molecular controls for SARS-CoV-2
April 23, 2020—Randox Laboratories has developed Randox Qnostics SARS-CoV-2 whole pathogen quality controls designed for laboratories managing COVID-19 testing to help ensure the accuracy and reliability of molecular assays used in the testing of suspected coronavirus samples.
Randox STI assay gets CE mark
April 2020—Randox announced that its Randox STI assay has received the CE mark. The multiplex assay detects 10 STIs, including co-infections, from a single patient sample. It tests simultaneously for Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis, Mycoplasma genitalium, Treponema pallidum, HSV-1, HSV-2, Haemophilus ducreyi, Mycoplasma hominis, and Ureaplasma urealyticum.
Vivalytic test for detecting SARS-CoV-2
April 1, 2020—Randox Laboratories and Bosch Healthcare Solutionswill launch this month the Vivalytic Viral Respiratory Tract Infection Array, which can identify SARS-CoV-2 and differentiate it from nine other respiratory infections with similar symptoms, including influenza and all known coronaviruses.
Randox STI assay gets CE mark
March 6, 2020—Randox announced that its Randox STI assay has received the CE mark. The multiplex assay detects 10 STIs, including co-infections, from a single patient sample.
Randox introduces test for COVID-19
Feb. 19, 2020—Randox Laboratories has introduced a test for the COVID-19 strain of coronavirus and nine other respiratory viruses.
Direct HbA1c testing in whole blood
December 2019—The Randox RX series provides laboratories with the capabilities of onboard HbA1c testing in whole blood on three fully automated RX analyzers—RX Modena, RX Imola, and RX Daytona+ —to accommodate rapid and reliable measurement of HbA1c in different laboratory settings.
Randox launches assay for CVD risk assessment
November 2019—Randox introduced a research use only sPLA2-IIA assay for use on a range of clinical chemistry analyzers. The latex-enhanced immunoturbidimetric assay measures sPLA2-IIA mass levels.
Randox RX series gains NGSP certification
October 2019—Randox Laboratories announced that the NGSP has awarded it with a manufacturer certification for direct HbA1c testing on three of the company’s clinical chemistry analyzers, the RX Modena, RX Imola, and RX Daytona+.